OncBioMune To Become Exclusive Distributor of Lipomed Drugs in Mexico

BATON ROUGE, LA--(Marketwired - August 10, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, a proprietary cancer vaccine technology and commercialization of a portfolio of products internationally, is pleased to announce written confirmation that the Company has been designated as the exclusive distributor of the product portfolio of Lipomed AG. Lipomed is a world leader for Reference Standards with specialization in the research, development and manufacturing of pharmaceuticals and products for the treatment of rare diseases from its state-of-the-art production facilities in Arlesheim, Switzerland.

OncBioMune intends to first focus on Litak (cladribine) and Dacin (dacarbazine), the two drugs that the Company believes can achieve immediate market penetration in Mexico. Litak is an antineoplastic agent primarily used for the treatment of hairy cell leukemia, with other uses for different types of blood cancers and lymphoma. Dacin is a chemotherapeutic drug currently used to treat various forms of cancer, including metastatic malignant melanoma and Hodgkin's disease.

"The partnership with Lipomed represents a milestone moment for us as part of our mission to introduce promising oncology products in Mexico," said Andrew Kucharchuk, President and Chief Financial Officer at OncBioMune. "We are working closely with Lipomed on finalizing the details of the agreement and look forward to providing guidance on expected time to launch and sales in the near future."

Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/.

About OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals is a revenue-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, including a proprietary vaccine technology designed to stimulate the immune system to attack tumor cells without damaging healthy tissue. OncBioMune is also involved in drug development and commercialization internationally through our wholly-owned subsidiary, OncBioMune México, S.A. De C.V. Our lead pipeline product, ProscaVax™, is scheduled to commence two, separate mid-stage clinical trials in 2017: a Phase 2 for early-stage prostate cancer at a major Northwest U.S. university cancer research hospital and a Phase 2/3 study in Mexico for late-stage prostate cancer patients. OncBioMune has a portfolio of targeted and licensed therapies, some of which are biosimilars and generics to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.

About Lipomed AG

Lipomed is a private Swiss Health Care Company. We are one of the leading companies for Reference Standards worldwide and specialized in the research, development and manufacturing of ethical pharmaceuticals and products for the treatment of rare diseases. Since 1993 Lipomed is dedicated to providing products and services of outstanding quality and expertise. We have our own GMP/GDP and ISO 9001 certified pharmaceutical production facilities in Arlesheim near Basel. We are also ISO/IEC 17025 accredited for testing of analytical reference standards and ISO Guide 34 accredited for the production of reference material. Our innovative products are marketed and distributed with offices and partners in more than 50 countries around the world.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceuticals' actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals' need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical's vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

Contact Information:

OncBioMune Pharmaceuticals, Inc.
Andrew Kucharchuk
President and Chief Financial Officer